NTRA Natera Inc
Company Analysis
Latest News
🔴 Natera is trading 4% down today amidst ongoing insider selling concerns
Natera is trading at $270.56 (-4.00%) today, as concerns over a recent surge in insider selling activity appear to be weighing on investor sentiment. • Reports...
Natera dominates cancer recurrence market, wins landmark FDA diagnostic approval
Natera holds a near-monopoly in the minimal residual disease (MRD) testing market. The Austin-based company's flagship product, Signatera, detects cancer...
Natera leads cancer recurrence market, holding 80% share with Signatera
Natera Inc. holds an estimated 80% market share in the minimal residual disease (MRD) testing market. The company’s flagship Signatera product uses...
Natera's first quarter 2026 revenue beat estimates by 33% on strong volume growth, prompting a raised full-year outlook.
Natera reported first quarter 2026 revenue of $696.6 million, a 38.8% increase year-over-year, and a net loss per share of ($0.60). The company processed over...
Natera Inc Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
For the first quarter of 2026, analysts expect Natera to deliver consensus revenue of $522.5 million and an EPS of -$0.53, with the stock currently trading at...
Natera Inc Q4 2025 Earnings Preview: What Analysts Expect on March 04, 2026
Analysts expect Natera to report Q4 2025 revenue of approximately $600.7 million and an EPS loss of $0.50, with the stock currently trading near $200 compared...
Natera's fourth quarter 2025 revenue beat estimates, driven by 55% growth in oncology test volume.
Natera reported fourth quarter 2025 revenue of $665.5 million, an increase of 39.8% year-over-year, driven by record test volumes and improvements in average...
Natera Inc Reports Q4 2025 Earnings on February 26, 2026
Wall Street expects Natera to report Q4 2025 revenue of approximately $660.45 million and a loss per share of $0.46, with the stock currently trading at...